Marquee Brands Enters Strategic Partnership With DAMAC Group for a Majority Interest in Roberto Cavalli
20.5.2026 20:30:00 CEST | Business Wire | Press Release
Marquee Brands, the premier global brand management company and leading brand accelerator, today announced a definitive agreement for a majority interest in Roberto Cavalli, through a strategic partnership with DAMAC Group, the leading Dubai-based global conglomerate and luxury real estate developer. The transaction is expected to close in the second quarter of 2026, after which DAMAC Group will remain a significant shareholder. Founded in Florence in 1970, Roberto Cavalli the iconic luxury house celebrated for its avant-garde design and distinct Italian craftsmanship joins Marquee Brands’ portfolio of timeless global brands, including Martha Stewart, Laura Ashley, Sur La Table, BCBGMAXAZRIA and Stance. The addition of Roberto Cavalli further strengthens Marquee Brands’ position as a leader in the luxury and lifestyle sectors, bringing total portfolio-wide retail sales to approximately US$5 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520070705/en/
Roberto Cavalli Spring/Summer 2026
“Roberto Cavalli stands as one of luxury’s defining Italian houses, with a bold creative identity and enduring brand ethos,” said Heath Golden, CEO, Marquee Brands. “We see extraordinary potential to build on that foundation through thoughtful brand stewardship and strategic expansion. In partnership with DAMAC, a leader in luxury real estate, we will continue to elevate the Roberto Cavalli experience worldwide.”
Hussain Sajwani, Founder of DAMAC Group, said: “Roberto Cavalli is one of the most distinctive luxury brands in the world. After several years of solidifying the brand’s foundation, we set out to find a strategic partner with the skillset to take the brand to the next level. We are confident Marquee Brands is the right partner to do so. Given our love for the brand and meaningful ongoing shareholdings, we look forward to supporting Marquee Brands’ efforts, by among other things, continuing to expand the Roberto Cavalli lifestyle through branded residences and hospitality projects in premier global destinations, an area that remains fully owned and operated by DAMAC. This collaboration marks an exciting new era for the brand. We look forward to its significant future expansion.”
Marquee Brands, owned by funds managed by Neuberger, a global investment management firm, continues to scale its global platform by acquiring heritage brands with deep consumer resonance. Roberto Cavalli marks the twenty-second brand in Marquee Brands’ portfolio.
“Marquee Brands has established a proven, capital‑efficient business model for driving growth through disciplined brand management, strategic partnerships and a long-term investment horizon,” said Zachary Sigel, Managing Director at Neuberger and Co-Founder of Marquee Brands. “The acquisition of Roberto Cavalli reinforces Neuberger’s confidence in the platform and its ability to continue to create value for investors.”
The partnership between Marquee Brands and DAMAC expands the global reach of the Roberto Cavalli brand, bringing together their complementary strengths and shared commitment to elevating the legendary Italian maison. Marquee Brands will accelerate Roberto Cavalli’s growth by introducing new categories, services and experiential touchpoints across Europe, the United Kingdom, the United States, the Middle East, Asia Pacific and Latin America.
DAMAC will continue to scale the brand’s presence through Roberto Cavalli-branded residences and hospitality projects across key global markets, reinforcing the brand’s luxury position and desirability. The partnership creates a powerful platform that unites Marquee Brands’ expertise in global brand development with DAMAC’s leadership in luxury real estate and hospitality, unlocking significant new opportunities for the future of Roberto Cavalli.
As part of the transaction, Marquee Brands announces Milan-based partner The Level Group (TLG) as its core operating partner. TLG will lead the development, manufacturing and distribution of the brand’s women’s and men’s collections, ensuring a unified and elevated product vision across key markets. In addition, TLG will assume responsibility for retail and e‑commerce operations and wholesale distribution in Europe and the United States, strengthening Roberto Cavalli’s direct-to-consumer presence and global retail strategy.
RBC Capital Markets served as financial advisor and Greenberg Traurig acted as legal advisor to Marquee Brands. BDA Partners served as financial advisor to DAMAC Properties.
ABOUT ROBERTO CAVALLI
Founded in 1970, Roberto Cavalli is a leading Italian brand in fashion, accessories and luxury lifestyle. Defined by a glamorous contemporary aesthetic, the brand is the quintessential expression of Italian excellence, craftsmanship and its Mediterranean origins. The Roberto Cavalli portfolio is positioned within the luxury segment and includes the Home, Junior, Eyewear, Perfumes, Watches and Just Cavalli collections. www.robertocavalli.com
ABOUT MARQUEE BRANDS
Marquee Brands is the premier accelerator of timeless brands, unlocking value and building global influence. With a focus on driving growth and building sustainable brand equity, we partner with best-in-class manufacturers, operators, retailers, and distributors to scale brands across markets and channels. Marquee Brands’ global portfolio spans three distinct platforms: Home & Culinary, Fashion & Lifestyle, Luxury and Active & Outdoor. The portfolio of brands includes Martha Stewart, Laura Ashley, Sur La Table, Emeril Lagasse, America’s Test Kitchen, BCBGMAXAZRIA, BCBG, Ben Sherman, Bruno Magli, Anti Social Social Club, Totes, Isotoner, Destination Maternity, Motherhood, A Pea in the Pod, Stance, Dakine and Body Glove. For more information visit, www.marqueebrands.com.
ABOUT NEUBERGER PRIVATE MARKETS
Neuberger Private Markets is a division of Neuberger and has been an active and successful private markets investor since 1987. Neuberger Private Markets invests across strategies, asset classes, and geographies for a large number of sophisticated and renowned institutions and individuals globally. As of December 31, 2025, Neuberger Private Markets manages over $155 billion of investor commitments across primaries, co-investments, secondaries, private credit, and specialty strategies. Neuberger Private Markets has an experienced and diverse team of over 500 professionals with a global presence in 17 offices globally.
ABOUT DAMAC GROUP
DAMAC Group is a global private business conglomerate founded by Hussain Sajwani in 1982. Starting in catering and logistics, it has expanded into diverse industries, including real estate, hospitality, data centers, fashion, and capital markets. DAMAC Properties is the largest private real estate developer in the UAE and the Middle East, and has been at the forefront of the Middle East’s luxury real estate market since 2002, delivering award-winning residential, commercial and leisure properties across the region and internationally, including in the UAE, Saudi Arabia, Qatar, Jordan, Lebanon, Iraq, the Maldives, Canada, the United States, as well as the United Kingdom. Since then, DAMAC has delivered more than 50,000 homes with over 55,000 more in diverse planning and development phases, joining forces with some of the world’s most eminent fashion and lifestyle brands to create tremendous living experiences, such as Roberto Cavalli and de GRISOGONO. With a consistent vision and momentum, DAMAC is building the next generation of luxury living across the globe. The Group also owns hotel assets under brands such as Radisson, Paramount, and Rotana, with an expanding hospitality portfolio. Beyond real estate, DAMAC is a leader in the data center industry through DAMAC Digital and has acquired luxury brands Roberto Cavalli and de GRISOGONO. Through DAMAC Capital, it invests in future-focused industries like tech, finance, and life sciences. Committed to social impact, the Hussain Sajwani – DAMAC Foundation supports education, innovation, and community-driven initiatives. For more information visit, www.damacgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520070705/en/
Contacts
For media inquiries, contact the Marquee Brands Press Office:
Email: corporate@marqueebrands.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom